Live Breaking News & Updates on Fate Therapeutics Daily
Stay updated with breaking news from Fate therapeutics daily. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) insider Brian T. Powl sold 3,854 shares of the firm’s stock in a transaction dated Wednesday, July 5th. The stock was sold at an average price of $4.87, for a total value of $18,768.98. Following the transaction, the insider now owns 41,146 shares of the company’s stock, valued […] ....
Victory Capital Management Inc. lowered its position in shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) by 22.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 759,802 shares of the biopharmaceutical company’s stock after selling 221,137 shares during the quarter. Victory Capital Management […] ....
Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) Director Yuan Xu sold 3,460 shares of the business’s stock in a transaction on Wednesday, June 14th. The shares were sold at an average price of $5.58, for a total transaction of $19,306.80. Following the transaction, the director now directly owns 9,934 shares of the company’s stock, valued […] ....
Eversept Partners LP lowered its stake in Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) by 69.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 43,562 shares of the biopharmaceutical company’s stock after selling 97,996 shares during the period. Eversept Partners LP’s holdings in Fate Therapeutics […] ....
Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Rating) have received an average recommendation of “Hold” from the twenty-two research firms that are currently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and five have issued a buy rating on the […] ....